Novartis Investigative Site

San Gil 684031

2 studies enrolling now · 7 studies all time

What they study most

Cardiovascular Disease and Lipoprotein(a), Chagas Disease, Heart Failure With Preserved Ejection Fraction, Hypercholesterolemia, Primary Prevention of Atherosclerotic Cardiovascular Disease

Studies at this site

• An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230) — Recruiting now
• A Study of Efficacy, Safety, Tolerability of LXE408 in Participants With Chronic Chagas Disease. — Recruiting now
• A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients. — Running, not enrolling
• Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD — Running, not enrolling
• Efficacy and Safety of Inclisiran as Monotherapy in Patients With Primary Hypercholesterolemia Not Receiving Lipid-lowering Therapy. — Completed
• Lipoprotein(a) in Patients With Cardiovascular Disease (CVD) — Completed
• A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients — Completed